Puma Biotechnology Inc.’s tyrosine kinase inhibitor neratinib, for extended adjuvant treatment of breast cancer: In its Phase
III ExteNET clinical trial, neratinib
demonstrated significantly higher
disease-free survival rates compared to
placebo after adjuvant treatment with
Herceptin for early-stage HER2-positive
breast cancer. This therapy is awaiting
FDA filing in first-half 2015, and potential
approval and launch in the second half.
Bristol-Myers Squibb Co.’s PD-1
immune checkpoint inhibitor Opdivo
(nivolumab), for previously treated
advanced melanoma patients: In its
Phase III trial, CheckMate-066, the pri-
mary endpoint of overall survival was
met. It emerged that the one-year sur-
vival rate was 73 percent for nivolumab
against 42 percent for the chemotherapy
dacarbazine (DTIC) in patients with
treatment-naïve BRAF wild-type ad-
vanced melanoma. The PDUFA goal date
was March 30, 2015, but FDA approved
the new medicine in December 2014.
Novartis AG’s selective IL-17A inhibi-
tor secukinumab, for the treatment of
plaque psoriasis: In the Phase III trial
FIXTURE, the drug was shown to be sig-
nificantly more effective in clearing skin
lesions than Pfizer Inc.’s Enbrel. In Octo-
ber 2014, FDA’s advisory committee rec-
ommended approval for secukinumab.
Anticipate a successful product launch in
the first quarter of 2015.
Novartis’ angiotensin receptor neprilysin inhibitor (ARNi) LCZ696, for the
treatment of heart failure: LCZ696 has
exhibited statistically superior data to
enalapril. Expect this treatment to be introduced in the second half of 2015.
AbbVie Inc.’s ABT-450/ritonavir
co-formulated with ombitasvir (ABT-
267), and dasabuvir (ABT-333) with
or without ribavirin for the treatment
of hepatitis C: This interferon-free, all-
oral regimen is supported by six Phase
III clinical trials. This triple combina-
tion therapy will likely be commercially
launched in first-quarter 2015.
GlaxoSmithKline plc’s RTS,S is expected to be the first malaria vaccine to
reach the market. GlaxoSmithKline submitted a regulatory application to the European Medicines Agency in July 2014;
launch is anticipated in 2015.
Sanofi Pasteur SA’s Dengue Vaccine is also expected to have a first-mov-er advantage, with FDA approval in 2015.
Ebola virus vaccines consisting of
cAd3-ZEBOV by GlaxoSmithKline,
PSC-1001 by NewLink Genetics Corp.,
and potentially an unnamed vaccine developed by Johnson & Johnson are
anticipated to be entering Phase III trials
in 2015. medadnews
Frost & Sullivan’s Life Sciences consultants have named seven
developmental compounds as the most promising therapeutics to
watch in 2015.
Compounds to watch
Content Licensing for
Every Marketing Strategy
Marketing solutions ;t for:
• Direct Mail
• Print Advertising
• Tradeshow/POP Displays
• Social Media
• Radio & Television
Logo Licensing | Reprints | Eprints | Plaques
For more information, call Wright’s Media at 877.652.5295 or visit our
website at www.wrightsmedia.com
Leverage branded content from Med Ad News to create a more powerful
and sophisticated statement about your product, service, or company in
your next marketing campaign. Contact Wright’s Media to find out more
about how we can customize your acknowledgements and recognitions to
enhance your marketing strategies.